Biofrontera Warrants Stock Debt To Equity
BFRIW Stock | USD 0.13 0.05 64.77% |
Biofrontera Warrants fundamentals help investors to digest information that contributes to Biofrontera Warrants' financial success or failures. It also enables traders to predict the movement of Biofrontera Stock. The fundamental analysis module provides a way to measure Biofrontera Warrants' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Biofrontera Warrants stock.
Last Reported | Projected for Next Year | ||
Debt To Equity | 0.96 | 1.01 |
Biofrontera | Debt To Equity |
Biofrontera Warrants Company Debt To Equity Analysis
Biofrontera Warrants' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Biofrontera Warrants Debt To Equity | 1.01 |
Most of Biofrontera Warrants' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biofrontera Warrants is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Biofrontera Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Biofrontera Warrants is extremely important. It helps to project a fair market value of Biofrontera Stock properly, considering its historical fundamentals such as Debt To Equity. Since Biofrontera Warrants' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biofrontera Warrants' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biofrontera Warrants' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition |
Biofrontera Total Stockholder Equity
Total Stockholder Equity |
|
Biofrontera Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biofrontera Warrants' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biofrontera Warrants could also be used in its relative valuation, which is a method of valuing Biofrontera Warrants by comparing valuation metrics of similar companies.Biofrontera Warrants is currently under evaluation in debt to equity category among its peers.
Biofrontera Fundamentals
Return On Equity | -1.49 | ||||
Return On Asset | -0.4 | ||||
Profit Margin | (0.38) % | ||||
Operating Margin | (0.65) % | ||||
Number Of Shares Shorted | 660 | ||||
Revenue | 34.07 M | ||||
EBITDA | (18.45 M) | ||||
Net Income | (20.13 M) | ||||
Total Debt | 5.4 M | ||||
Book Value Per Share | 3.16 X | ||||
Cash Flow From Operations | (24.89 M) | ||||
Earnings Per Share | (1.30) X | ||||
Number Of Employees | 83 | ||||
Beta | 0.51 | ||||
Total Asset | 27.93 M | ||||
Retained Earnings | (99.65 M) | ||||
Working Capital | 4.99 M | ||||
Net Asset | 27.93 M |
About Biofrontera Warrants Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biofrontera Warrants's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera Warrants using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera Warrants based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biofrontera Stock Analysis
When running Biofrontera Warrants' price analysis, check to measure Biofrontera Warrants' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera Warrants is operating at the current time. Most of Biofrontera Warrants' value examination focuses on studying past and present price action to predict the probability of Biofrontera Warrants' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera Warrants' price. Additionally, you may evaluate how the addition of Biofrontera Warrants to your portfolios can decrease your overall portfolio volatility.